Senses Disorder TRIZ Cases

De-cellularized human amniotic fluid retains biological activity through controlled refrigeration and lyophilization processes.

Water-soluble tomato extract reduces angiotensin-converting enzyme activity to modulate blood pressure.

Heat treatment and filtration sterilize hyaluronic acid solutions, preventing molecular weight degradation during large-scale production.

Preliminary genome editing with CRISPR-Cas9 overcomes adeno-associated virus silencing to sustain transgene expression and treat retinal degenerations.

Naphthyridine compounds inhibit androgen receptor activity, resolving poor affinity and mutation resistance in prostate cancer treatment.

EPI0030 humanized rabbit monoclonal antibody binds VEGF with 0.485 nM dissociation constant via specific variable domain sequences.

Genetically engineered producer cells decrease surface MHC-I expression to generate enveloped viral particles with reduced immunogenicity.

Combining hyaluronate with ectoine and panthenol increases tear film thickness while reducing surface tension for prolonged dry eye treatment.

Segmented DNA-chip probe arrays enable high-throughput in vitro genotyping with precise signal detection.

2,4-Diphenyl-1,3-dioxane compounds modulate PPAR activity and inhibit thromboxane synthase.

Small molecule diphenyl derivatives bypass downregulated growth factor receptors to enhance wound healing efficacy in protease-rich environments.

CRISPR editing removes the IVS40 mutation from the USH2A gene, eliminating the disease progression associated with Usher Syndrome Type 2A.

Anti-connexin polynucleotides downregulate connexin expression to inhibit gap junction formation and reduce excessive matrix accumulation in fibrotic tissues.

New pyrazolone derivatives mimic natural stabilizers to prevent HIF degradation, addressing the lack of effective activators for ischemic conditions.

An interleukin-15 variant adds an amphipathic alpha helix at the carboxyl terminus, resolving low prokaryotic expression yields and purification difficulties.

Antisense oligonucleotides inhibit natural antisense transcripts, resolving inefficient GDNF modulation by targeting specific reverse complement sequences.

An AAV-S capsid vector delivers a clarin-1 transgene to cochlear and retinal cells, resolving limited serotype coverage in Usher syndrome treatment.

N-(amino-heteroaryl)-1H-indole-2-carboxamide derivatives resolve insufficient TRPV1 receptor antagonistic activity by introducing localized functional groups.

Fluorinated and alkylated bile acid derivatives inhibit tissue degeneration through endoplasmic stress response modulation.

A phenoxybenzamine and polymyxin E combination kills multiplying and non-multiplying microorganisms through synergistic bactericidal activity.

Novel chemical structures in Formula I improve glycemic control and tissue fuel metabolism while avoiding side effects like weight gain and liver toxicity.

Recombinant ankyrin repeat proteins bind VEGF-A165 with high affinity, blocking receptor interaction while sparing anti-angiogenic isoforms.

Antisense oligonucleotides hybridize to natural antisense transcripts to modulate brain derived neurotrophic factor expression.

Engineered IL-6 antibodies target site II to reduce disease severity while minimizing systemic adverse reactions.

Small molecule IRE1α inhibitors block oligomerization and RNase activity, reducing ER stress-induced apoptosis in diabetic conditions.

Boldo and meadowsweet extracts stimulate cathelicidin production to treat microbial infections without triggering pro-inflammatory responses.

Substituted pyrazino[2,3-b]pyrazines inhibit RORγ while maintaining metabolic stability to treat autoimmune disorders.

Pyridazinone compounds modulate Met kinase activity, reducing tumor growth and inflammation while minimizing adverse effects.

Novel quinoxalinone derivative acts as a glucocorticoid receptor agonist to treat inflammatory conditions.

Novel HtrA1 inhibitors block protease activity, preventing extracellular matrix degradation and halting dry AMD progression.

A hydrophilic polymer layer enhances water wettability on medical device substrates through a simplified heating process.

Programmable DNA binding proteins enhance genome editing efficiency and specificity by overcoming chromatin structure barriers.

Bicyclic heterocyclyl compounds inhibit semaphorin function, resolving the lack of effective inhibitors for treating nerve injury and neurological diseases.

Combines L-carnitine with a statin to reduce insulin resistance and protein glycosylation, avoiding severe side effects of conventional antidiabetic drugs.

An APP-derived peptide selectively downregulates TNF-R2 to reduce photoreceptor apoptosis, resolving the trade-off between receptor inhibition and selectivity.

Electrophilic peptide inhibitors selectively inactivate proteasomes in senescent cells, sparing healthy tissue from damage.

Using (+)-azasetron enantiomer treats ear disorders by increasing bioavailability while reducing adverse events common with racemic compounds.

Humanized antibodies bind amyloid beta epitopes to inhibit monomer aggregation and disaggregate preformed fibrils, reducing plaque burden.

Isoindole-imide compounds modulate TNF-alpha levels to overcome treatment resistance and reduce toxicity in cancer therapy.

CXCR3 activators inhibit aberrant angiogenesis by targeting the CXCR3 receptor pathway to prevent new blood vessel formation.

Quinone derivatives scavenge reactive oxygen species to treat oxidative stress disorders where existing drugs fail.

A viral vector delivers CYP4V2 to retinal cells using specific promoters.

An electrochemically activated salt solution treats eye infections through oxidative stress without preservatives.

Introducing non-natural nucleotides with artificial base pairs boosts aptamer production efficiency while maintaining selectivity and reducing cytotoxicity.

Targeting HSP70 and HSP90 levels, the peptide reduces tumor growth while minimizing side effects from conventional anti-angiogenic therapies.

Autoclaving brinzolamide with surfactants prevents harmful crystal formation while maintaining therapeutic pressure reduction.